MK-3415A
Phase 3Biologic
Merck & Co.MK-3415A is one of 28 biologic programs targeting Clostridium Difficile Infection. It is currently in Phase 3.
1
Indications
2
Total Trials
0
Active Trials
27
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
53 competitors in Clostridium Difficile Infection
#DrugCompanyPhaseTrials
1Dificlir
Merck & Co.Approved
Vancocin
HHikma Pharmaceuticals LLC
Approved
ZINPLAVA
Merck & Co.Approved
Prilosec
DDexcel Pharma Technologies Ltd.
Approved
Alinia
RRomark Laboratories L.C.
Phase 3
Imodium
KKenvue Brands
Phase 3
Flagyl
DDePuy Orthopaedics
Phase 2
Glutamine
SanofiPhase 2
MK-6072
Merck & Co.Phase 3
Antibiotics
MMelinta Therapeutics, Inc.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Clostridium Difficile Infection2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for MK-3415A. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 3[1]
- Company